Introduction

0930–0940  David Hartley, The XLP Research Trust and Professor Bobby Gaspar, UCL Institute of Child Health, UK

Clinical Section

0940–1000  Clinical manifestations of XLP1 and outcome—Dr Claire Booth, Molecular Immunology Unit, UCL Institute of Child Health, United Kingdom

1000–1020  X-linked dysgammaglobulin caused by hypomorphic XIAP mutation, Dr Hirokazu Kanegane, Department of Pediatrics/University of Toyama, Japan

1020–1040  Clinical and molecular comparison between CD27 and ITK deficiency—two fatal EBV Lymphoproliferative diseases in males and females—Professor Ardt Borkhardt, Heinrich–Heine—University Dusseldorp, Germany

1040–1100  Break

XLP2/XIAP Pathogenesis

1100–1120  Physiological activities of XIAP, the protein affected in type 2 XLP disease—Dr Colin Duckett, University of Michigan, USA

1120–1140  Role of innate-like T cells and the NOD2 pathway in the pathophysiology of the X-Linked Lymphoproliferative syndrome type 2 (XLP2) —Dr Sylvain Latour, INSERM 768, Hospital Necker–Enfants Maladies, Paris, France

1140–1200  An international survey of transplant outcomes for XIAP deficiency—Dr Rebecca Marsh, Cincinnati Children’s Hospital Medical Center, USA

1200–1310  Lunch

XLP1/SAP Pathogenesis

1310–1330  Positive and negative signalling through SLAM receptors regulate synapse organisation and set thresholds of CD8-mediated cytolysis—Dr Jennifer Cannons, National Human Genome Research Project, National Institute of Health, Bethesda, USA

1330–1350  Expansion of somatically reverted memory CD8+ T cells in XLP patients due to selective pressure from Epstein Barr virus—Professor Stuart Tangye, Garvan Institute of Medical Research, Sydney, Australia

1350–1410  Molecular function of SAP and NTB-A in promoting restimulation—induced cell death of activated T cells—Dr Andrew Snow, Uniformed Services University of the Health Sciences, Bethesda, USA

1410–1430  Break

1430–1450  Conditional elimination of the adaptor molecule SAP reveals an essential role in invariant NKT cell cytotoxicity in vitro and in vivo—Dr Kim Nichols, The Children’s Hospital of Philadelphia, USA

1450–1510  SAP-Mediated inhibition of diacylglycerol kinase alpha regulates TCR-induced diacylglycerol signalling—Professor Gianluca Baldanzi, Universita del Piemonte Orientale Amedeo Avogadro, Novara, Italy

Gene Therapy

1510–1530  Lentiviral vector mediated gene therapy for X-linked Lymphoproliferative disease restores humoral and cellular functions—Dr Christine Rivat, UCL Institute of Child Health, UK

Summary

1530–1600  Professor Bobby Gaspar, UCL Institute of Child Health, London, UK